Cargando…

Population Pharmacokinetics of Necitumumab in Cancer Patients

Necitumumab is a second-generation, recombinant, human immunoglobulin G1, epidermal growth factor (EGFR) receptor antibody that specifically blocks the ligand binding site of EGFR. Necitumumab potentially acts by blocking ligand epidermal growth factor (EGF) binding-mediated activation of the EGFR s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Long, Amanda, Chigutsa, Emmanuel, Wallin, Johan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2016
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5385201/ https://www.ncbi.nlm.nih.gov/pubmed/27696220 http://dx.doi.org/10.1007/s40262-016-0452-x

Ejemplares similares

Exposure–Response Analysis of Necitumumab Efficacy in Squamous Non‐Small Cell Lung Cancer Patients
por: Chigutsa, E, et al.
Publicado: (2017)

Population Pharmacokinetics and Pharmacodynamics of the Neutralizing Antibodies Bamlanivimab and Etesevimab in Patients With Mild to Moderate COVID‐19 Infection
por: Chigutsa, Emmanuel, et al.
Publicado: (2021)

Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer
por: Elez, E, et al.
Publicado: (2016)

Clinical potential of necitumumab in non-small cell lung carcinoma
por: Genova, Carlo, et al.
Publicado: (2016)

Spotlight on necitumumab in the treatment of non-small-cell lung carcinoma
por: Thakur, Manish K, et al.
Publicado: (2017)

Development and Application of a Mechanistic Population Modeling Approach to Describe Abemaciclib Pharmacokinetics
por: Chigutsa, Emmanuel, et al.
Publicado: (2020)

Dose Rationale of Nasal Glucagon in Japanese Pediatric Patients with Diabetes Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation
por: Nasu, Risa, et al.
Publicado: (2023)

Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study
por: Murata, Yasunori, et al.
Publicado: (2023)

Lung squamous cell carcinoma with severe hypomagnesemia due to cisplatin plus gemcitabine in combination with necitumumab therapy: A case report
por: Nakao, Akira, et al.
Publicado: (2021)

The Budget Impact of Including Necitumumab on the Formulary for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer: U.S. Commercial Payer and Medicare Perspectives
por: Bly, Christopher A., et al.
Publicado: (2018)

Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania
por: Denti, Paolo, et al.
Publicado: (2015)

Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study
por: Park, Keunchil, et al.
Publicado: (2017)

Pooled Population Pharmacokinetic Analysis for Exploring Ciprofloxacin Pharmacokinetic Variability in Intensive Care Patients
por: Guo, Tingjie, et al.
Publicado: (2022)

Pharmacokinetics and Safety of Vortioxetine in the Chinese Population
por: Miao, Jia, et al.
Publicado: (2019)

Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin plus necitumumab versus gemcitabine–cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer
por: Paz-Ares, L., et al.
Publicado: (2016)

Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer
por: Gupta, Neeraj, et al.
Publicado: (2020)

Population Pharmacokinetic Modeling of Lucitanib in Patients with Advanced Cancer
por: Liao, Mingxiang, et al.
Publicado: (2022)

Population pharmacokinetics of bevacizumab in cancer patients with external validation
por: Han, Kelong, et al.
Publicado: (2016)

Nonlinear Population Pharmacokinetics of Sirolimus in Patients With Advanced Cancer
por: Wu, K, et al.
Publicado: (2012)

Efficacy and Safety of Ultra-Rapid Lispro in Younger and Older Patients with Type 2 Diabetes: Randomized Double-Blind PRONTO-T2D Study
por: Zhang, Qianyi, et al.
Publicado: (2022)

Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer
por: Adiwijaya, BS, et al.
Publicado: (2017)

PK/PD modeling links accelerated resolution of COVID‐19‐related clinical symptoms to SARS‐CoV‐2 viral load reduction in patients following treatment with Bamlanivimab alone or Bamlanivimab and Etesevimab together
por: Ernest, C. Steven, et al.
Publicado: (2022)

Population Pharmacokinetic Meta-Analysis of Vortioxetine in Healthy Individuals
por: Areberg, Johan, et al.
Publicado: (2014)

A Population Pharmacokinetic and Pharmacodynamic Analysis of Abemaciclib in a Phase I Clinical Trial in Cancer Patients
por: Tate, Sonya C., et al.
Publicado: (2017)

Docetaxel population pharmacokinetic modelling and simulation in Chinese cancer patients
por: Wei, Jian, et al.
Publicado: (2022)

Population Pharmacokinetic and Pharmacodynamic Modeling of Fesoterodine in Pediatric Patients with Neurogenic Detrusor Overactivity
por: Sano, Yamato, et al.
Publicado: (2023)

A Prospective Population Pharmacokinetic Study on Morphine Metabolism in Cancer Patients
por: Oosten, Astrid W., et al.
Publicado: (2016)

Population Pharmacokinetic Meta-Analysis to Bridge Ferumoxytol Plasma Pharmacokinetics Across Populations
por: Plock, Nele, et al.
Publicado: (2014)

Population Pharmacokinetics of Dexmedetomidine in Critically Ill Patients
por: Välitalo, Pyry Antti, et al.
Publicado: (2013)

Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis
por: Savic, Radojka M., et al.
Publicado: (2017)

Population Pharmacokinetics of Sarilumab in Patients with Rheumatoid Arthritis
por: Xu, Christine, et al.
Publicado: (2019)

Population Pharmacokinetic Model and Pharmacokinetic Target Attainment of Micafungin in Intensive Care Unit Patients
por: Martial, Lisa C., et al.
Publicado: (2017)

Population Pharmacokinetic and Pharmacodynamic Modeling of LY2510924 in Patients With Advanced Cancer
por: Bihorel, S, et al.
Publicado: (2017)

Population Pharmacokinetics of Nivolumab in Japanese Patients with Nonsmall Cell Lung Cancer
por: Tohi, Makiko, et al.
Publicado: (2023)

Population Pharmacokinetics of CC-122
por: Cheng, Yiming, et al.
Publicado: (2021)

Population Pharmacokinetics of Vancomycin in Thai Patients
por: Purwonugroho, Tunggul Adi, et al.
Publicado: (2012)

Effect of ethnicity on vinorelbine pharmacokinetics: a population pharmacokinetics analysis
por: Pétain, Aurélie, et al.
Publicado: (2019)

Concordance of Vancomycin Population-Predicted Pharmacokinetics with Patient-Specific Pharmacokinetics in Adult Hospitalized Patients: A Case Series
por: Onor, IfeanyiChukwu O., et al.
Publicado: (2020)

Comparable Liraglutide Pharmacokinetics in Pediatric and Adult Populations with Type 2 Diabetes: A Population Pharmacokinetic Analysis
por: Petri, Kristin C. Carlsson, et al.
Publicado: (2015)

Population pharmacokinetics of clonazepam in saliva and plasma: Steps towards noninvasive pharmacokinetic studies in vulnerable populations
por: Kruizinga, Matthijs D., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ub3kmdftb80nk384ast6gmdq7e